Semaglutide
A GLP-1 receptor agonist best known as Ozempic/Wegovy, used for weight management and diabetes.
⚠ Research & Educational Use Only. Semaglutide is a research chemical documented here for scientific education. All information references peer-reviewed literature and preclinical/clinical study data. Not for human consumption. Not medical advice. Consult a licensed researcher or healthcare professional before any laboratory use.
- Significant weight loss (15–21% body weight in clinical trials)
- Improved glycemic control in type 2 diabetes
- Reduced cardiovascular risk (SELECT trial: 20% reduction in MACE)
- Semaglutide is not FDA-approved for human use. It is a research chemical for scientific study only.
Research At a Glance
- Significant weight loss (15–21% body weight in clinical trials)
- Improved glycemic control in type 2 diabetes
- Reduced cardiovascular risk (SELECT trial: 20% reduction in MACE)
- Decreased appetite and reduced food cravings
What is Semaglutide?
Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist that mimics the GLP-1 incretin hormone. It works by stimulating insulin secretion in response to elevated blood glucose, suppressing glucagon release, slowing gastric emptying, and reducing appetite by acting on satiety centers in the brain. Originally approved by the FDA as Ozempic for type 2 diabetes management (2017), it was later approved as Wegovy at higher doses for chronic weight management (2021). Research has demonstrated unprecedented levels of weight loss (15–21% body weight) not previously seen with any other pharmaceutical agent.
Key Research Benefits
Documented effects observed in preclinical and clinical studies on Semaglutide. See all Metabolic & Weight peptides for comparison.
Common Stacks
Semaglutide is frequently combined with the following peptides for synergistic effects. Click any peptide to compare profiles before deciding.
The CagriSema combination - cagrilintide's amylin receptor mechanism adds 5-7% additional weight loss on top of semaglutide alone.
BPC-157 is frequently used to mitigate the GI side effects (nausea, gut dysmotility) associated with GLP-1 agonists.
Tirzepatide's dual GIP/GLP-1 mechanism produces greater weight loss than semaglutide alone - often compared as alternative rather than combined.
Side Effects & Risks
Adverse effects reported in the research literature. All data sourced from preclinical and clinical study reports.
Dosing Data from the Literature
Doses referenced below are sourced from published preclinical and clinical studies. Use the peptide dose calculator to convert these values to injection volume.
Standard clinical dosing: Start at 0.25 mg/week for 4 weeks, increase to 0.5 mg/week, then titrate up to 1 mg (diabetes) or 2.4 mg/week (weight management) over 16-20 weeks. Research peptide dosing may differ — typically starts at 0.25 mg/week and titrates more slowly.
Administration in Research Settings
Standard reconstitution and administration methodology for laboratory research use.
Approved as a once-weekly subcutaneous injection (abdomen, thigh, or upper arm). Administered the same day each week. Can be taken with or without food. Titrate slowly to minimize GI side effects. Ensure adequate protein intake (1.6–2.2 g/kg body weight) and resistance training to preserve muscle mass.
Research Video
Explore Further
Quick Reference
Research Articles
- Semaglutide Dosage Guide: Reconstitution, Dose Escalation, and Injection Protocol7 min read
- Peptides for Fat Loss: GLP-1, Fragment 176-191, AOD-9604, and Growth Hormone Research9 min read
- Semaglutide vs Liraglutide: GLP-1 Agonist Potency, Duration, and Clinical Outcomes8 min read
- Fragment 176-191 vs AOD-9604: The Fat-Loss Peptide Comparison7 min read
Research Use Only
This information is for educational research purposes only. This is not medical advice. Consult a qualified healthcare professional.